

# MSD Announcement

---

## NewCo will unleash potential in women's health and other areas

MSD is spinning off products from its women's health, legacy brands, and biosimilars franchises into a new independent, publicly traded company ("NewCo")

"We have made the decision to separate into two growth companies: MSD and NewCo. By optimising our human health portfolio, MSD can move closer to its aspiration of being the premier research-intensive biopharmaceutical company, while also properly prioritising a set of products at NewCo that are important to public health and the patients who rely on them, and which present real opportunities for growth."

**Kenneth C. Frazier**  
MSD Chairman and CEO

---

Better meeting the needs of patients and  
improving public health globally

MSD will continue to be the  
premier research-intensive  
biopharmaceutical company

Focusing on current  
growth pillars:



Oncology



Vaccines



Hospital



Animal Health

NewCo will unleash  
potential in women's  
health and other areas



Women's Health



Legacy Brands



Biosimilars

---

For further information please click [here](#).